Paolo Strati MDAssistant Professor, Department of Lymphoma and Myeloma & Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Paolo Strati is a Hematology-Oncology Fellow at MD Anderson Cancer Center (MDACC), Houston, TX. He received his medical degree cum laude from Universita’ Vita-Salute San Raffaele of Milan (Italy) in 2008, and then completed his first Internal Medicine Residency at the same institution, and a second one at the Mayo Clinic (Rochester, MN). He has also completed a 2-year Leukemia Clinical Fellowship at MDACC and a brief Malignant Hematology Clinical Research Fellowship at the Queen Mary University, Barts Cancer Center, in London (UK).
His main research interest is to develop novel therapeutic strategies to eradicate minimal residual disease (MRD) in patients with low grade lymphoma, with special focus on chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), through the use of immunomodulatory therapies.
His research activity has so far translated in the publication of 50 peer-reviewed papers and 59 abstracts presentations at major international meetings, including ASH and ASCO. His efforts have been acknowledged with multiple awards over the last years, including the Celgene Award as Future Leader in Hematology and the ASCO Young Investigator Award. In addition, during his residency at the Mayo Clinic, in light of his background and achievements, he was promoted to the academic rank of Assistant Professor.
Dr. Strati plans to develop an academic career and establish himself as a clinical and translational leader in the field of low grade lymphoma, with particular emphasis on tumor microenvironment targeting, at a major academic center in the United States.
Recent Contributions to PracticeUpdate:
- Association of Monoclonal B-Cell Lymphocytosis With Future Hematologic Malignancy and Survival
- Preexisting and Treatment-Emergent Autoimmune Cytopenias in Patients With CLL Treated With Targeted Drugs
- International Prognostic Score for Asymptomatic Early-Stage Chronic Lymphocytic Leukemia
- A New Polygenic Risk Score Predicts CLL